HIPK2 inhibits cell metastasis and improves chemosensitivity in esophageal squamous cell carcinoma

ZHENG ZHANG1, PENGHAO WEN2, FANGFANG LI1, CHUANSHAN YAO1, TONGFU WANG1, BING LIANG1, QINGLE YANG1, LEI MA1 and LIMIN HE1

1Department of Clinical Oncology, The First People’s Hospital of Nanyang; 2Department of Clinical Oncology, The Affiliated Nanshi Hospital of Henan University, Nanyang, Henan 473000, P.R. China

Received March 9, 2017; Accepted September 22, 2017

DOI: 10.3892/etm.2017.5468

Abstract. Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive and lethal malignancies worldwide. At present, the underlying mechanisms of ESCC development and progression are poorly understood. Previous studies have demonstrated that homeodomain-interacting protein kinase-2 (HIPK2) serves an important role in cancer biology, particularly in proliferation and metastasis. However, the role of HIPK2 in ESCC cells remains unclear. In the current study, the expression of HIPK2 in ESCC specimens, adjacent non-cancerous tissues and cell lines was assessed using reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The effects of HIPK2 on cell metastasis, epithelial-mesenchymal transition (EMT) and proliferation were studied using a Transwell assay, RT-qPCR and a Cell Counting Kit-8 assay, respectively. The results indicated that HIPK2 expression was downregulated in ESCC specimens and cell lines, and HIPK2 expression was associated with tumor invasion and lymph node metastasis. Functional studies demonstrated that HIPK2 overexpression inhibited cell metastasis and EMT. Furthermore, HIPK2 overexpression suppressed cell viability during cisplatin treatment. These results suggest that HIPK2 serves an important role in regulating metastasis and the chemosensitivity of ESCC cells, implicating the potential application of HIPK2 in ESCC therapy.

Introduction

Esophageal squamous cell carcinoma (ESCC) is one of the most aggressive and lethal malignancies worldwide (1). Nutritional deficiencies, nitrosamine-rich or mycotoxin-contaminated foods and low socioeconomic status are likely to contribute to ESCC (1,2). It has been reported that heavy smoking and alcohol consumption are key environmental risk factors for ESCC (3,4). Dysphagia is the most common symptom of ESCC. Although surgery is considered to be the most effective treatment for ESCC in terms of locoregional control and long-term survival, recurrence and metastases to the liver occur in the majority of cases following complete resection, resulting in a 15-25% five-year survival rate in patients with ESCC (5). Therefore, the identification of molecular mechanisms that pinpoint biologically aggressive tumors is critical for the effective management of ESCC.

Homeodomain-interacting protein kinase-2 (HIPK2) is a member of an evolutionary conserved family of serine/threonine kinases and is considered to be a tumor suppressor that modulates a number of basic cellular processes, including apoptosis, proliferation, differentiation and metastasis (6-9). It has previously been demonstrated that HIPK2 mediates apoptosis and epithelial-mesenchymal transition (EMT) of renal tubular epithelial cells contributing to fibrosis, implying that it may be a potential target for anti-fibrosis therapy (10). HIPK2 has also been demonstrated to activate the p53 protein via direct binding and phosphorylation at serine 46 following severe DNA damage (11). Puca et al (12) demonstrated that HIPK2 is an important regulator of p53 activity in response to chemotherapeutic agent cisplatin and Lazzari et al (13) indicated that HIPK2 knockdown induces resistance to multiple anticancer agents, including doxorubicin and cisplatin. HIPK2-mediated vimentin downregulation may contribute to the inhibition of breast cancer cell invasion (14). In bladder cancer, HIPK2 inhibition promotes EMT and subsequent cell invasion, at least in part by activating Wnt signaling (15). However, the biological role and clinical significance of HIPK2 in ESCC remain largely unknown.

The present study aimed to investigate whether HIPK2 regulates metastasis and chemosensitivity in ESCC. It was identified that upregulation of HIPK2 inhibits cell metastasis and suppresses cell viability during cisplatin treatment, implicating a potential application of HIPK2 in ESCC therapy.

Materials and methods

ESCC specimens. A total of 56 paired ESCC specimens (34 males and 22 females) and adjacent non-cancerous tissues...
were collected from the Department Of Thoracic Surgery of the First People's Hospital of Nanyang (Nanyang, China) between March 2015 and February 2016. The mean age was 63.22 years (range, 44-84 years). According to the AJCC tumor stage (16), 30 patients had stage I-2 and 26 had stage 3-4. Samples were immediately frozen in liquid nitrogen and stored at -80˚C. Written informed consent was obtained from all patients prior to their involvement in the current study. None of the patients had undergone preoperative anticancer therapies. The study was approved by the Ethics Committee of the First People's Hospital of Nanyang.

**Cell lines and transfection.** Human ESCC cell lines EC109 and EC9706 clone EC1 (EC1) and the human epithelial cell line Het-1a were maintained in RPMI-1640 (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) supplemented with 10% fetal bovine serum (FBS, Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) in a humidified atmosphere with 5% CO₂ at 37˚C. The cisplatin-resistant sub-line (EC109/cis) was established by continuous exposure to increasing concentrations (0.1, 0.2, 0.4, 0.6 and 1 µg/ml) cisplatin over 12 months (17). After continuous exposure to cisplatin for 2 days, the medium was replaced with a fresh cisplatin free medium until the surviving cells recovered favorably. When cells grew to the 60-70% confluency, cisplatin was added to the medium again. Each concentration was repeated six times.

The pEGFP-N1 and pEGFP-N1-HIPK2 plasmids were purchased from Shanghai GenePharma Co., Ltd. (Shanghai, China) and verified by sequencing using an ABI 3730xl automated sequencer (Applied Biosystems; Thermo Fisher Scientific, Inc.). For plasmid transfection, 3×10⁵ cells (EC109, EC1, EC109/cis) were seeded in 6-well plates 24 h prior to transfection with 4 µg plasmid DNA using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. Transfected cells were selected using G418 (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) 2 days after transfection to generate stably transduced monoclonal cell lines. After 14 days of screening, stable transfectants were selected for further amplification, and were then tested by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) for overexpression of HIPK2.

**RT-qPCR.** Total RNA was extracted from cells (Het-1a, EC109, EC1, EC109/cis) and ESCC specimens using TRIzol according to the manufacturer's protocol (Invitrogen; Thermo Fisher Scientific, Inc.), and RT reactions were performed using a PrimeScript™ II 1st Strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's protocol. PCR analysis was performed using SYBR® Premix Ex Taq™ II reagent (Takara Biotechnology Co., Ltd.) on the ABI 7500 Fast System (Applied Biosystems; Thermo Fisher Scientific, Inc.). The reaction protocol involved heating for 10 sec at 95°C, followed by 40 cycles of amplification (5 sec at 95°C and 30 sec at 60°C). The primer sequences (HIPK2, GAPDH, E-cadherin and N-cadherin) used are presented in Table I. GAPDH was used as the internal standard. Data analysis was performed using the 2^-ΔΔCq method (18). Each sample was analyzed in triplicate.

Transwell migration and invasion assay. Transwell cell migration and Matrigel invasion assays (8 µm pore size) were utilized to estimate the migration and invasion ability of cells (EC109 and EC1) in vitro. For the invasion assay, Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) was added to the upper surface of the membrane and allowed to gel at 37°C for 30 min. A total of 600 µl of RPMI-1640 medium with 10% FBS was placed in the bottom compartment of the chamber. Harvested EC109 and EC1 cells (2×10⁵) in 200 µl of serum-free RPMI 1640 medium were added into the upper compartment of the chamber. Following 24 h of incubation at 37°C in an atmosphere containing 5% CO₂, cells that had migrated or invaded to the basal side of the membrane were stained with crystal violet (0.005%, Sigma-Aldrich; Merck KGaA) for 20 min at room temperature and counted as the number of cells per field of view under a light microscope at x200 magnification in 10 random fields.

**Cell Counting Kit (CCK)-8 assay.** Cells (EC109-Vector/HIPK2, EC109/cis-Vector/HIPK2) were seeded in triplicate on a 96-well plate (Corning Incorporated, Corning, NY, USA) at a density of 5×10⁴ cells/well. Cell proliferation was assessed after 24, 48 and 72 h using the CCK-8 (Dojindo Molecular Technologies, Inc., Kumamoto, Japan) method according to the manufacturer's protocol.

**Statistical analysis.** All data are expressed as the mean ± standard deviation. The differences between two groups were analyzed using Student's t-test. The difference between three groups was assessed by one-way analysis of variance followed by Tukey's post hoc test. All statistical analyses were performed using SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate a statistically significant difference.

**Results**

**HIPK2 expression is decreased in ESCC cells.** The expression of HIPK2 in 56 paired ESCC tissues was determined using RT-qPCR. The expression of HIPK2 mRNA was significantly decreased in ESCC tissues compared with their adjacent non-cancerous tissues (P<0.01; Fig. 1A). To further evaluate the role of HIPK2 in human ESCC, the association between HIPK2 and clinical parameters, including age, sex, TNM and cancer grade, was evaluated. Decreased HIPK2 expression was significantly associated with tumor invasion (P<0.05; Fig. 1B) and lymph node metastasis (P<0.05; Fig. 1C). HIPK2 was not significantly associated with other clinical characteristics, including age, gender, differentiation and tumor stage (data not shown). The expression of HIPK2 in ESCC cell lines EC109 and EC1 and esophageal epithelial cell line Het-1a was then determined. HIPK2 was significantly downregulated in EC109 and EC1 cells compared with Het-1a cells (both P<0.01; Fig. 1D). These results indicated that HIPK2 downregulation may be associated with ESCC metastasis and serve a tumor suppressive role in ESCC.

**HIPK2 overexpression inhibits cell migration and invasion in vitro.** To further investigate the role of HIPK2 in cell invasion, ESCC cells stably transfected with a control vector or HIPK2
were analyzed. The expression of HIPK2 was confirmed in EC109 (Fig. 2A) and EC1 cells (Fig. 2B) transfected with HIPK2 or the control vector. HIPK2 mRNA was significantly increased in EC109 and EC1 cells transfected with HIPK2 compared with cells transfected with the control vector (both P<0.001). In addition, HIPK2 overexpression significantly inhibited ESCC cell migration and invasion in vitro (P<0.05; Fig. 2C and D). These results suggest that HIPK2 negatively regulates ESCC cell migration and invasion.

**HIPK2 overexpression suppresses EMT.** The initial stage of metastasis is dependent on the prominent biological event referred to as EMT, which is characterized by specific morphogenetic changes, loss of cell adhesion and increased cell movement (19). The mechanism by which HIPK2 regulates ESCC cell metastasis was investigated. HIPK2 overexpression decreased the expression of the mesenchymal marker neural (N)-cadherin mRNA in EC109 (P<0.01; Fig. 3A) and EC1 cells (P<0.01; Fig. 3B). HIPK2 overexpression significantly increased the expression of epithelial (E)-cadherin mRNA in EC109 and EC1 cells (both P<0.05; Fig. 3C and D). These results indicate that EMT was suppressed by HIPK2 upregulation.

**HIPK2 overexpression inhibits cell viability during cisplatin treatment.** Cisplatin-based chemotherapy is a common regimen applied for the treatment of ESCC (20). Chemoresistance is a primary cause of treatment failure in patients with cancer (21). To clarify the molecular mechanisms underlying cisplatin resistance in ESCC cells, a cisplatin resistant subline was established. The EC109 ESCC cell line was treated with cisplatin in gradually increasing concentrations to establish a cisplatin resistant cell line (EC109/cis). HIPK2 was significantly downregulated in chemoresistant EC109/cis cells (P<0.01; Fig. 4A), indicating that HIPK2 downregulation may be associated with cisplatin resistance in ESCC cells. The

### Table I. Primer sequences.

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward (5’-3’)</th>
<th>Reverse (5’-3’)</th>
<th>Product size (bp)</th>
</tr>
</thead>
<tbody>
<tr>
<td>GAPDH</td>
<td>GCACCGTCAAGGCTGAGAAC</td>
<td>TGGTGAAGACGCAGCTGGGA</td>
<td>138</td>
</tr>
<tr>
<td>HIPK2</td>
<td>CCCGTGTAACGAGGTATGCG</td>
<td>AGTTGGAAACTCGGCTCTATTTC</td>
<td>109</td>
</tr>
<tr>
<td>N-cadherin</td>
<td>AGCCAAACCTTAACTGAGGAGT</td>
<td>GGCAAGTGTAGTTGAGGGAGTG</td>
<td>136</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>ATTTTCCCCCTCGACACCCCGAT</td>
<td>TCCCCAGGCGTAGACCAAGA</td>
<td>109</td>
</tr>
</tbody>
</table>

HIPK2, homeodomain-interacting protein kinase-2; N, neural; E, epithelial.

---

Figure 1. HIPK2 expression is downregulated in ESCC cells and associated with tumor invasion and lymph node metastasis. HIPK2 expression was assessed in (A) 56 paired ESCC specimens and adjacent non-cancerous tissues, (B) T1-2 (n=30) and T3-4 (n=26) groups according to the depth of tumor invasion, (C) lymph node metastasis negative and positive groups and (D) human ESCC cell lines EC109 and EC1 and human epithelial cell line Het-1a. Each test was repeated in triplicate. *P<0.05 and **P<0.01. HIPK2, homeodomain-interacting protein kinase-2; ESCC, esophageal squamous cell carcinoma; T, tumor; Normal, adjacent non-cancerous tissue.
The effect of HIPK2 on cisplatin sensitivity in ESCC cells was also investigated. HIPK2 overexpression significantly decreased EC109 cell viability compared with EC109 cells transfected with the control vector during cisplatin treatment (P<0.001; Fig. 4B). In EC109/cis cells, cisplatin treatment caused a modest decrease in cell viability compared with EC109 cells, whereas overexpression of HIPK2 in EC109/cis cells restored the sensitivity of chemoresistant cells to cisplatin (P<0.01; Fig. 4C and D). The overexpression of HIPK2 had no significant effect on the proliferation of EC109 cells compared with EC109/cis cells. These results suggest that HIPK2 increased the cisplatin sensitivity of ESCC cells.
Discussion

The results of the present study indicate that HIPK2 is downregulated in ESCC tissues compared with their adjacent non-cancerous tissues. This result is consistent with previous studies, in which HIPK2 downregulation has been reported in bladder cancer, breast cancer and ovarian cancer (12,14,22). HIPK2 overexpression has also been demonstrated in patients with cervical and colorectal cancer with familial adenomatous polyposis (23,24). The current study demonstrated that the low expression of HIPK2 was associated with lymph node metastasis. These results suggest that HIPK2 may be a candidate tumor suppressor associated with metastasis.

The role of lymphatic metastasis in aggressive malignancies has been demonstrated in multiple studies and the occurrence of regional lymph node metastasis at an early stage is a crucial step in cancer progression (25,26). To investigate the effect of HIPK2 on cell metastasis, stable HIPK2 overexpression and empty vector cell lines were established. Upregulation of HIPK2 inhibited the migration and invasion of ESCC cells. HIPK2 decreased the level of mesenchymal marker N-cadherin mRNA, which is one of the most important markers of EMT (27). By contrast, HIPK2 increased the expression of epithelial marker E-cadherin. The current study therefore demonstrates that HIPK2 suppresses EMT, which is an important step in cancer metastasis. Cell characteristics are altered during EMT, resulting in altered cell-cell and cell-matrix interactions, cell motility and invasiveness (28). Chung et al (29) previously reported that N-cadherin suppresses RAC-γ serine/threonine-protein kinase to promote cell motility in mammary tumor cells. Furthermore, Qian et al (30) demonstrated that N-cadherin served a pivotal role in promoting metastasis through the regulation of extracellular-regulated kinase and protein kinase B. Nodale et al (14) demonstrated that MDA-MB-231 cells transfected with HIPK2 had decreased levels of vimentin mRNA that strongly correlated with re-expression of E-cadherin, which is indicative of a reversion of the EMT phenotype. Tan et al (15) also demonstrated that HIPK2 knockdown increased the levels of the mesenchymal markers N-cadherin and fibronectin and decreased the level of E-cadherin, indicating that EMT is induced by HIPK2 downregulation. The results of the current study are consistent with previous studies.

Accumulating evidence also suggests that EMT is associated with the onset of drug resistance and tumor relapses, representing an escape mechanism from apoptosis (31). Systematic chemotherapy is an important clinical strategy used in the treatment of ESCC, which targets tumor cells and reduces tumor recurrence (32). It serves an important role in ESCC treatment, especially for patients with advanced and metastatic ESCC cancer (33). Acquired chemoresistance of a tumor leads to regrowth during anticancer agent treatment, even if the tumor initially responds to the anticancer agents (34). Lin et al (22) indicated that HIPK2 sensitized chemoresistant bladder cancer cells to cisplatin. In the present study, it was demonstrated that HIPK2 expression levels were significantly downregulated in EC109/cis cells compared with EC109 cells. The forced expression of HIPK2 reduced cell viability during cisplatin treatment in EC109 cells and HIPK2 overexpression ameliorated cisplatin resistance in EC109/cis cells. HIPK2 has been demonstrated to be an important regulator of p53 activity in response to chemotherapeutic agents (35). In addition, HIPK2 overexpression in resensitized chemoresistant p53 wild type ovarian cancer cells to chemotherapy by mediating
p53 phosphorylation (12). Consistent with previous studies, the present study demonstrated that HIPK2 ameliorated chemoresistance, and this may be via regulation of p53 function, which will be investigated in the future.

In conclusion, the results of the current study demonstrate that HIPK2 is downregulated in ESCC specimens and is associated with metastasis. The results suggest that HIPK2 overexpression suppresses EMT and subsequent cell metastasis. Furthermore, HIPK2 overexpression partially ameliorates cisplatin resistance in EC109/cis cells. These results suggest that HIPK2 serves an important role in regulating the metastasis and chemoresistance of ESCC cells, suggesting a potential application of HIPK2 in ESCC therapy.

References

17. ZHANG et al: HIPK2 EXPRESSION IN ESCC